Group 1 - The core viewpoint of the news highlights the growth and investment opportunities in the brain-computer interface (BCI) market, particularly in China, with significant funding and technological advancements being made by domestic companies [1][2] - The China Medical and Medical Device Innovation Index (931484) has shown a positive performance, with a 0.78% increase, and notable gains in constituent stocks such as TeBao Bio and XinHe Cheng [1] - The global brain-computer interface market is projected to reach approximately $2.62 billion in 2024, with an expected growth to $2.94 billion in 2025 and a compound annual growth rate of 17.35% over the next decade [2] Group 2 - The Chinese brain-computer interface market is anticipated to grow from 3.2 billion yuan in 2024 to 6.14 billion yuan by 2028, indicating a strong domestic market potential [2] - Recent funding of 300 million yuan in A+ round financing for ZhiRan Medical will be utilized for large-scale clinical trials and product iterations, marking a significant step in the application of invasive brain-computer interfaces [1] - The top ten weighted stocks in the China Medical and Medical Device Innovation Index account for 63.9% of the index, with companies like WuXi AppTec and Mindray Medical leading the list [2]

智冉医疗解决脑机接口安全性难题，脑机接口作为顶层战略稳步推进 2月9日上午，书记在北京国家信创园考察科技创新工作，接见北京脑科学与类脑研究所的所长罗敏敏等代表。 1月30日，中共中央政治局举行第二十四次集体学习，脑机接口作为"十五五"六大未来产业被重点学习。 我国高通量、可拉伸柔性电极解决行业痛点 北京脑科学与类脑研究所资深研究员、智冉医疗创始人方英领衔的团队，研制 智冉医疗解决脑机接口安全性难题，脑机接口作为顶层战略稳步推进 北京脑科学与类脑研究所资深研究员、智冉医疗创始人方英领衔的团队，研制出一款高通量、可拉伸柔性电极， 该技术解决了传统柔性电极在大脑动态运动时易移位、易脱出的核心问题，为植入式脑机接口长期稳定性提供了 底层解决方案，该成果于2月5日在《NatureElectronics》发表。 国产脑机全链布局，比肩甚至超越Neuralink 马斯克创办的Neuralink公司，首例人体植入术后数周，高达85%的柔性电极丝从该患者的脑组织中脱出。 智冉医疗已拥有电极植入手术机器人及微纳加工车间，可拉伸柔性电极达1024通道，实现从技术路径到工程参 数，比肩甚至超越Neuralink。 受益标的：创新医疗 ...

Group 1: CRO Industry Insights - Since 2025, domestic CRO orders have shown a trend of simultaneous volume and price increase, benefiting from the overseas expansion of innovative drugs and stable financing recovery [1] - Multiple CROs have accelerated new order signing quarterly, achieving double-digit growth in project volume, with a price increase trend observed in experimental monkeys, safety evaluation quotes, and clinical project pricing since Q4 [1] - The performance of CROs is expected to enter an improvement cycle by 2026, driven by strong customer demand and the continuous strengthening of China's global competitiveness in innovative drugs [1] Group 2: Innovative Drug Market Dynamics - Despite previous adjustments in the innovative drug sector, the logic of strengthening global competitiveness, successful overseas expansion, and realization of commercial profits remains unchanged [1] - In the past two years, China has experienced a "big year" for innovative drug overseas expansion, with record highs in both the number and value of licensing-out transactions [1] - In 2025, the number of new drug license-out transactions in China is expected to reach 158, with a total transaction scale of $135.7 billion and an upfront payment scale of $7 billion, marking a ten-year high in both transaction quantity and value [1] Group 3: Brain-Computer Interface (BCI) Developments - The BCI sector is advancing with multiple technological routes underpinned by AI integration and supportive policies, accelerating the commercialization growth cycle [2] - BCIs serve as a direct information exchange channel between the biological brain and external devices, enabling brain function replacement, repair, enhancement, and optimization [2] - In the global landscape, the US leads in invasive technologies while China has made breakthroughs in non-invasive and language decoding fields, with both countries showing minimal technological lag [2] Group 4: Policy and Capital Support for BCI - The BCI industry is included in the "14th Five-Year Plan," with various policies supporting technological innovation, application scenarios, and medical insurance payments, facilitating industry standardization and clinical transformation [2] - Capital investment in the BCI sector has significantly increased, with a multiple growth in financing events and amounts expected by 2025, indicating a strong recovery in investor interest [2] - Although the financing structure shows early-stage characteristics, leading companies have received substantial capital injections, leading to a gradual emergence of industrial clustering effects [2]

近期，随着创新药企业陆续披露2025年报及业绩预告，多家企业展现出良好的经营改善态势，在报告期 内实现亏损收窄甚至业绩转正，释放出积极信号。在此背景下，创新药及相关板块再引关注。公告显 示，工银瑞信中证港股通医疗主题交易型开放式指数证券投资基金（简称：港股通医疗ETF工银；代 码：159167）将于2026年2月12日起在深交所上市交易。 公开资料显示，港股通医疗ETF工银（159167）紧密跟踪中证港股通医疗主题指数（代码： 932069.CSI），该指数锚定医疗创新，全面覆盖港股"CXO +互联网医疗+医疗器械+创新药"等医药各领 域核心龙头，并囊括脑机接口、AI医疗、高端医疗器械等热门主题；该指数弹性足，估值具有吸引 力。Wind数据显示，截至2026年2月10日，中证港股通医疗主题指数目前市盈率（TTM）为32.85倍， 处于发布以来48.16%分位，指数当前或未被高估，或仍具有吸引力。 国金证券指出，2025年中国新药License-out交易数量达158笔、总规模1357亿美元，创近十年新高；出 海BD繁荣不仅显著提振短期业绩预期，更推动国产新药国际化开发进程与远期价值提升。申万宏源研 究研报观点 ...

■近日，国家标准委批准发布403项国家标准，涉及新兴领域、安全生产、百姓生活等方面。其中，脑 机接口、数字孪生等5项国家标准将大幅降低企业开发建设成本，为前沿技术应用落地和持续迭代提供 科学路径。 ■国铁太原局：10日上午，雄忻高铁最后一座隧道常青隧道实现顺利贯通，标志着雄忻高铁全线所有隧 道全部贯通，为后续工程有序推进奠定基础。 ■市场监管总局组织全国各地市场监管部门开展春节热销食品安全专项抽检6.7万批次，合格率为 98.38%，总体食品安全状况良好。 ■中国物流与采购联合会：2025年全国社会物流总额超368万亿元，物流业总收入为14.3万亿元，同比增 长4.1%。 ■各省区市近日陆续发布2025年经济数据指标。其中，广东、江苏、山东等GDP排名前十省份地区生产 总值同比增长5.1%，对全国经济增长的贡献率为62.2%，拉动全国经济增长3.1个百分点。 ■2026年亚太经合组织（APEC）第一次高官会10日上午在广州开幕。今年是中国第三次担任APEC东道 主。 ■联合国秘书长古特雷斯9日发表农历新年致辞，向中国人民拜年。 ■10日上午，习近平总书记在北京考察调研，先后来到新街口街道父母食堂、银龄老年公寓 ...

去年8月，智冉医疗刚获得超3亿元A轮融资。时隔半年再次拿到大额融资，且老股东集体加注，可见投资机构对智冉医疗侵入式 脑机接口全栈能力的认可。 智冉医疗创始人、CEO宋麒告诉36氪，从创立之初，智冉就坚定做侵入式脑机接口，一方面是因为团队在侵入式脑机接口底层技 术拥有深厚的技术积累；另一方面，脑机接口的未来终局不会限于瘫痪患者脑控外设、功能重建等，而要实现高效的人机信息互 通，只有侵入式脑机接口能够做到真正高通量、高质量的信号读写。 "柔性电极"这一核心部件，可谓是侵入式脑机接口赛道的关键入场券。人的大脑是非常柔软的组织，电极植入大脑皮层后，如何 确保长期不移位，并减少因免疫反应产生瘢痕、而导致脑电信号衰减等，成为重要研发方向。 智冉医疗创始人方英在柔性高通量电极与神经记录调控研究领域深耕多年，有多项突破性成果。研发的高通量"可拉伸柔性电 极"在植入大脑后，能够动态跟随大脑的搏动与颅内位移，确保了电极在脑组织中的长期稳定性。而且，相比于传统线性电极， 这款可拉伸电极在脑内也更加"柔软"，对脑组织的机械损伤更低。当前，智冉医疗已经研制出基于可拉伸柔性电极的高通量无线 侵入式脑机接口系统。 时 隔半年再次拿到大额融 ...

Core Insights - The article highlights a breakthrough in the field of invasive brain-machine interfaces (BMIs) achieved by a research team led by Fang Ying from Zhiren Medical, which successfully developed a high-throughput, stretchable flexible electrode that addresses the core challenges of traditional flexible electrodes in dynamic brain movements [2][12]. Group 1: Technological Advancements - The newly developed stretchable flexible electrode overcomes the limitations of traditional linear electrodes, which struggle to maintain stability during brain movements, thus providing a foundational solution for the long-term stability of invasive BMIs [2][4]. - The innovative design of the stretchable electrode allows it to dynamically adapt to the brain's pulsations and movements, ensuring long-term stability within the brain tissue [6][9]. - The research team demonstrated that the stretchable flexible electrode could achieve long-term stable recordings of neuronal activity in non-human primates, marking a significant milestone for clinical applications of invasive BMIs [8][12]. Group 2: Market Position and Future Implications - Zhiren Medical is positioned to lead the invasive BMI sector, with its breakthrough technology aligning with national strategic plans, thereby facilitating the transition from laboratory research to large-scale clinical applications [12][13]. - The advancements in invasive BMIs are expected to integrate seamlessly into everyday life, enhancing human-machine interactions in dynamic environments, such as extreme sports, without the risk of device displacement or brain injury [12][13]. - As the technology matures, China is poised to gain a significant competitive edge in the global invasive BMI market, leveraging its technological advancements to influence industry development [13].

Core Viewpoint - The company is actively pursuing international expansion and product innovation while addressing currency fluctuations and market competition challenges. Group 1: Stock Performance and Market Activity - As of February 10, 2026, the company's stock closed at 190.36 yuan, with a slight increase of 0.63% and a trading volume of 51,700 shares, resulting in a transaction value of 983 million yuan [1] - On February 10, 2026, there was a net inflow of 45.8035 million yuan from main funds, indicating significant buying interest [10] Group 2: International Listing and Regulatory Approvals - The company submitted an application for H-share listing on the Hong Kong Stock Exchange on November 10, 2025, which is pending approval from various regulatory bodies [2] Group 3: Currency Impact on Financial Performance - Approximately 50% of the company's sales revenue comes from overseas, primarily settled in USD and EUR, making it susceptible to fluctuations in the RMB exchange rate, which can affect revenue and profit margins [3] - The company is implementing strategies such as foreign exchange hedging and fixed-rate agreements to mitigate the impact of currency fluctuations on its business operations [3] Group 4: Product and Market Positioning - The company has established a strong global network in R&D, manufacturing, marketing, and service, with its six major product lines ranking among the top three in global markets [4] - As of June 30, 2025, the company's products were sold in over 190 countries, with overseas revenue accounting for approximately 45% of total revenue in 2024 [4] - In the European and American markets, the company achieved over 5.5 billion yuan in revenue in 2024, representing 15% of total revenue, highlighting its brand strength and sales growth [4] Group 5: AI and Innovation Strategy - The company emphasizes its commitment to medical AI, with applications in critical care and various clinical scenarios, although it faces challenges in market perception and growth potential [5] - There is a call for the company to enhance its corporate culture and innovation focus to bridge the gap with international competitors and improve product pricing power [6] Group 6: Shareholder Engagement and Future Plans - As of September 30, 2025, the total number of shareholders was 108,835 [7] - The company plans to release its annual report for 2025 on March 31, 2026, which will provide insights into its financial performance [8]

Group 1 - The company, Mindray Medical (300760.SZ), has stated that it is not currently involved in the brain-computer interface business as mentioned by an investor inquiry on the interactive platform [2]

2026年2月4日，博睿康技术（上海）股份有限公司正式向上海证监局提交上市辅导备案，辅导机构为中信证券，正式踏上A股IPO之路。 01） 不慌实验室 "第一股"竞争进入白热化 这家脱胎于清华大学神经工程实验室、深耕脑机接口十余年的企业，一跃成为资本市场焦点，也让国产脑机接口"第一股"的竞争进入白热化阶段。 自2015年天使轮融资启动，到2024年完成D轮融资，博睿康在近十年时间里累计完成6轮融资，松禾资本、熔拓兴兆、常州科教城产业基金、红杉中国等 知名机构密集入局，资本持续加注，印证了赛道热度与团队价值。 股权结构显示，公司控股股东为胥红来，持股13.90%，黄肖山持股11.85%，红杉恒辰持股8.94%，股权相对分散，但机构背书充足、科研背景扎实。 在脑机接口从科幻概念走向产业落地的关键节点，博睿康选择登陆资本市场，不仅是企业发展的重要里程碑，更成为观察中国脑机接口从技术研发走向商 业化、资本化的重要窗口，标志着国产脑机接口正式迈入资本市场主战场。 博睿康的核心价值，在于依托清华大学自主创新的脑机接口技术，构建"硬件+软件+算法"一体化能力，是国内少数实现从科研到临床全链条布局的脑机 接口企业。 公司专注神 ...